EGFR R832L

CI-VAR-00003913Explore in graph →CIViC 2741

Curated evidence

Evidence by cancer (2 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–2 of 2 evidence items across 1 cancer context on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Lung Non-Small Cell Carcinoma2
EGFR R832L	Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor	Predictive	C	Supports Sensitivity Response	1	submitted	EID7368 In this systematic pubmed search, EGFR variants associated with Response to EGFR-directed therapy were summarized. One Patient with an EGFR R832L Mutation achieved stable disease with an EGFR Inhibito… (full text at CIViC) PMID 23344264 · Yeh et al., 2013 · Open in CIViC	civic
EGFR R832L	Gefitinib	Predictive	C	Supports Sensitivity Response	2	submitted	EID7367 106 Chinese patients who received second-line gefitinib were screened for EGFR mutations. One Patient with an EGFR R832L Mutation achieved stable disease. Treatment was ongoing after 7 months at the t… (full text at CIViC) PMID 19020901 · Xu et al., 2009 ·

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.